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Abstract
Background: Argonaute 2 (AGO2), a central component of RNA-induced silencing complex, plays critical roles in
cancer. We examined whether the single nucleotide polymorphisms (SNPs) of AGO2 were related to the risk of
nasopharyngeal carcinoma (NPC).
Methods: Twenty-five tag SNPs within AGO2 were genotyped in Guangxi population consisting of 855 NPC
patients and 1036 controls. The SNPs significantly associated with NPC were further replicated in Guangdong
population consisting of 996 NPC patients and 972 controls. Functional experiments were conducted to examine
the biologic roles of AGO2 in NPC.
Results: A significantly increased risk of advanced lymph node metastasis of NPC was identified for the AGO2
rs3928672 GA + AA genotype compared with GG genotype in both the Guangxi and Guangdong populations
(combined odd ratio = 2.08, 95 % confidence interval = 1.44-3.01, P = 8.60 × 10−5). Moreover, the AGO2 protein
expression levels of rs3928672 GA + AA genotype carriers were higher than the GG genotype carriers in the
NPC tissues (P = 0.041), and AGO2 was significantly over-expressed in NPC tissues compared with non-cancerous
nasopharyngeal tissues (P = 0.011). In addition, AGO2 knockdown reduced cell proliferation, induced apoptosis,
and inhibited migration of NPC cells. Furthermore, gene expression microarray showed that genes altered following
AGO2 knockdown were clustered in tumorigenesis and metastasis relevant pathways.
Conclusions: Our findings suggest that the genetic polymorphism in AGO2 may be a risk factor for the advanced
lymph node metastasis of NPC in Chinese populations, and AGO2 acts as an oncogene in the development of NPC.
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Background
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy with striking racial and geographic distribution
differences. It is particularly prevalent among popula-
tions from southern China, Southeast Asia, northern
Africa and Alaska. These incidence rates are approxi-
mately 100-fold higher than in the Caucasian populations
[1]. Several environmental factors, including infection
with the Epstein-Barr virus (EBV), long-term cigarette
smoking, occupational exposure to formaldehyde, and
various dietary factors, have been reported to confer the
risk of developing NPC [2]. Furthermore, numerous gen-
etic linkage and association studies have reported a few
genes contributing to the risk of this malignancy [3, 4].
The identification of susceptibility genes contributing to
NPC would assist in predicting individual and population
risk of NPC development and would help to clarify the
pathogenesis relevant to this disorder.
Argonaute 2 (AGO2), a member of the Argonaute
protein family, can bind microRNAs (miRNAs) or short
interfering RNAs (siRNAs) and mediate the repression
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of specific target RNAs either by degrading RNA or inhi-
biting translation [5]. Of the four human AGO proteins,
AGO2 is the only member with intrinsic endoribonuclease
activity and essential non-redundant slicer-independent
function within the mammalian miRNA pathway [6].
Recently, alterations (genomic amplifications and/or over-
expression) of the AGO2 gene have been extensively de-
scribed in a variety of cancers [7–11], and these alterations
have been shown to be linked with an increased metastasis
[11–13] and poorer prognosis [12]. Further studies indi-
cated that the AGO2 is involved in several steps of cancer
development, including cell proliferation, differentiation,
apoptosis, migration and invasion [8–10, 14, 15]. With
regard to NPC, the elevated mRNA expressions of AGO2
were observed in tumor tissues and latent membrane
protein 1 (LMP1)-positive tumors compared with normal
adjacent nasopharyngeal epithelium tissues and LMP1-
negative tumors, respectively [16]. Taken together, these
studies suggest that the AGO2 may play crucial roles in
the cancer development and progression.
Theoretically, the genetic variants such as single nu-
cleotide polymorphisms (SNPs) within the AGO2 gene,
which may alter the expression of AGO2 and then influ-
ence the miRNAs processing and function, could result
in genotype-dependent differences in risk of cancers.
Indeed, there is increasing evidence that the genetic vari-
ants in the AGO2 gene are associated with the risk or
development of several cancers, including breast cancer
[17, 18] and malignant peripheral nerve sheath tumor
[19]. The role of genetic variants within AGO2 in NPC,
however, has never been specifically investigated. In the
present study, we examined whether the genetic variation
in the AGO2 gene affect the risk or severity of NPC in the
Chinese populations. We also evaluated the biologic roles
of AGO2 in the development of NPC by functional assays.
Methods
Study population
This study consisted of two populations of patients
with NPC and control subjects resided in Guangxi and
Guangdong province, respectively, both of which were
well-known high-risk regions for NPC located in southern
China (Additional file 1: Table S1). The Guangxi popula-
tion, which contained 855 incident patients with NPC and
1036 controls, has been described in detail previously [20].
Briefly, all subjects were unrelated ethnic adult Chinese
and residents in Nanning city (Nanning, China) and the
surrounding regions. All patients were newly diagnosed
and pathologically confirmed, and were consecutively
recruited between September 2003 and January 2008 at
the Guangxi Cancer Hospital (Nanning, China). Patients
that received chemotherapy or radiotherapy prior to
surgery or had other type of cancer were excluded from
this study. Tumor staging was performed according to the
tumor-node-metastasis (TNM) classification by the 1997
American Joint Committee on Cancer (AJCC) system. All
TNM classifications were determined by senior patholo-
gists of the hospital on the basis of the postoperative
histopathologic examination. All the controls were re-
cruited in the same regions during the same time that the
NPC cases were collected. The selection criteria for the
controls included no individual history of cancer and
frequency matching to the cases on sex and age (± 5 years).
The Guangdong population, which contained 997 NPC
patients and 972 controls, has been described in detail
previously [3]. Briefly, all subjects were unrelated ethnic
adult Chinese and residents in Guangdong province. All
patients were consecutively recruited between October
2005 and October 2007 from Sun Yat-sen University
Cancer Center (SYSUCC) in Guangzhou city (Guangzhou,
China). All patients were histopathologically diagnosed
by at least two pathologists according to the World
Health Organization (WHO) classification. During the
same period, control subjects were recruited from physical
examination centers of several large comprehensive
hospitals in local communities in Guangdong and were
frequency matched to the cases by age (± 5 years), sex,
geographic region and ethnicity. All the subjects were
interviewed for collection of personal information on
demographic factors, medical history, cigarette smoking
and alcohol use via structured questionnaire. This study
was approved by the Ethics Committee of Beijing Institute
of Radiation Medicine (Beijing, China). At recruitment,
the written informed consent was obtained from all the
participants involved in this study.
From the Guangxi population of 855 patients with
incident NPC, 37 patients who had undergone resec-
tion before receiving any further treatment at Guangxi
Cancer Hospital were selected, and primary NPC biopsies
were collected from them (Additional file 1: Table S2).
The histological type of all tumor tissues was poorly differ-
entiated squamous cell carcinoma (SCC). Histological
non-cancerous nasopharyngeal epithelium tissues were
collected from 18 of the 1036 control subjects (Additional
file 1: Table S2). All the tissues were fixed in paraformal-
dehyde, embedded in paraffin wax, and prepared for
subsequent immunohistochemical staining.
SNP selection and genotyping
Twenty-five SNPs in the AGO2 gene were selected for
genotyping in our study (Table 1). These SNPs were
chosen on the basis of previous reports of their association
with the risk for cancer, or with potential function, and a
comprehensive tag SNP approach. Two SNPs (rs2292779
and rs7005286) significantly associated with cancer in
previous studies [18, 19] were directly selected in our
study. Two SNPs (rs4961280 and rs11996715) located in
the promoter region (−1809A/C and −1686 A/C) of
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AGO2, were selected as they could alter the expression of
AGO2. Tag SNPs of the AGO2 gene were selected from
the Han Chinese in Beijing, China (CHB) HapMap data-
base (HapMap release 27, February 2009) using Haplo-
View (pairwise r2 > 0.8) [21]. To ensure enough statistical
power, a value of 0.10 of minor allele frequency (MAF)
was set as the threshold value of inclusion in this study.
Finally, 25 tag SNPs were selected to capture the AGO2
gene.
All SNPs were genotyped using GenomeLab SNPstream
Genotyping System according to the manufacturer’s
instructions (Beckman Coulter, USA) as previously
described [22]. This platform uses a single base pair
extension reaction to incorporate two-color fluorescence
terminal nucleotides which are detected by a specialized
imager. Details of the primer sequences are listed in
Additional file 1: Table S3. The genotype data were
analyzed by GenomeLab SNPstream version 2.2 soft-
ware (Beckman Coulter, USA). To ensure genotyping
quality, we genotyped 20 randomly selected duplicate
samples and 4 blanks in each 384-well plate and obtained
a concordance rate of >99 %.
Immunohistochemistry in NPC tissues and non-cancerous
nasopharyngeal tissues
The paraformaldehyde-fixed and paraffin-embedded NPC
tissues (n = 37) and non-cancerous nasopharyngeal tissues
(n = 18) (Additional file 1: Table S2) were analyzed for
protein expression of AGO2. Two slides from each
biopsy were stained with hematoxylin and eosin for
routine histological evaluation. Histologic slides with
tissue sections were subjected to immunohistochemis-
try (IHC) as previously described [20, 22], using the
primary antibody raised against AGO2 (diluted 1:200;
ab57113, Abcam, UK). Negative controls and positive
controls were performed at the same time. Photographs
were taken (BX51 microscopic/Digital Camera System;
Olympus) for study comparison. The IHC signals were
scored as previously described [20, 22] by two pathologists
(Wu J and Huang W) who did not have knowledge of
ligand-binding assay results or patient outcome. Briefly, a
proportion score was assigned representing the estimated
proportion of positive staining tumor cells (0, none;
1, < 1/100; 2, 1/100 to < 1/10; 3, 1/10 to < 1/3; 4, 1/3 - 2/3;
5, > 2/3). Average estimated intensity of staining in posi-
tive cells was assigned an intensity score (0, none; 1, weak;
2, intermediate; 3, strong). The two parameters were com-
bined and resulting in an overall score (0 or 2–8). The
scores were classified into three groups: group 1 (score 0,
negative expression), group 2 (score 2–4, low expression)
and group 3 (score 5–8, high expression). A total of five
fields per slide were selected, counted, and averaged.
AGO2 knockdown in NPC cell line
The human nasopharyngeal carcinoma cell line CNE2Z
was obtained from the Peking Union Medical College
(Chinese Academy of Medical Science, China) and main-
tained in RPMI 1640 (Gibco-BRL, USA) supplemented
with 10 % fetal bovine serum (HyClone, USA) and 1 %
penicillin/streptomycin (Gibco-BRL, USA) at 37 °C under
a 5 % CO2 atmosphere. The AGO2 specific shRNA
expression vectors and the scrambled ineffective shRNA
cassette (as the negative control) in the pGPU6/GFP/Neo
plasmid were purchased from GenePharma (China). The
sequences of the three shRNAs directed against AGO2 are
as follows: sh1: 5’-GCAAGGATCGCATCTTCAAGG-3’;
sh2: 5’-GGTCTAAAGGTGGAGATAAGG-3’; and sh3: 5’-
GCCTGAAGATCAACGTCAAGC-3’. The sequence of




1 rs4961280 C/A 0.111 −1809 Promoter
2 rs11996715 C/A 0.430 −1686 Promoter
3 rs4961226 G/T 0.400 3050 Intron 1
4 rs10088596 C/T 0.453 5311 Intron 1
5 rs883596 G/C 0.105 9957 Intron 1
6 rs13261055 A/G 0.386 16208 Intron 1
7 rs7001653 G/A 0.444 24567 Intron 1
8 rs7819727 A/G 0.452 48394 Intron 1
9 rs7009635 T/C 0.367 50724 Intron 2
10 rs7005286 C/T 0.337 51145 Intron 2
11 rs11776034 C/G 0.211 53712 Intron 2
12 rs3735805 C/T 0.356 68083 Intron 3
13 rs2977490 A/G 0.453 72247 Intron 3
14 rs2292773 C/T 0.278 73107 Intron 4
15 rs3928672 G/A 0.222 73438 Intron 4
16 rs2271735 G/T 0.178 76295 Intron 6
17 rs2977481 G/C 0.183 83748 Intron 10
18 rs2292779 G/C 0.244 84394 Intron 11
19 rs2944764 C/T 0.239 84576 Intron 11
20 rs11166983 G/A 0.278 87519 Intron 11
21 rs12542354 C/T 0.239 89462 Intron 13
22 rs13252337 A/G 0.186 96222 Intron 16
23 rs2977469 G/A 0.465 96314 Intron 16
24 rs2977464 C/T 0.333 100412 Intron 16
25 rs2977462 T/C 0.467 102467 Intron 16
SNPs in bold were not in Hardy-Weinberg equilibrium (HWE) (rs883596 and
rs2977490, both P < 0.05) or failed genotyping (rs2977481) in the Guangxi
population
adbSNP ID number
bMinor allele frequencies in HapMap-HCB (HCB, unrelated Han Chinese in
Beijing, China)
cThe position of the SNPs is relative to the first nucleotide of the open reading
frame of the AGO2 gene, referred to as accession number NT_008046.15
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control shRNA is 5’-GTTCTCCGAACGTGTCACGT-3’.
A mixture of constructs including three AGO2 shRNAs or
the control shRNA construct was transfected into CNE2Z
cells using Lipofectamine 2000 (Invitrogen, USA). The
efficiency of RNA interfering was assessed by western blot
analysis.
Western blot
Cells were lysed in Laemmli sample buffer (Bio-Rad, USA)
with an EDTA-free, protease inhibitor cocktail (Roche,
USA). Proteins at the same amount were separated by
SDS-PAGE and transferred onto polyvinylidene difluoride
(PVDF) membranes (Millipore, USA). After probing with
primary and secondary antibody, antigen-antibody com-
plex was visualized by enhanced chemiluminescence-plus
reagent (Pierce Biotechnologies, USA). For AGO2, mouse
anti-AGO2 monoclonal antibody (diluted 1:1000; ab57113,
Abcam, UK) was used. As an internal control, mouse anti-
β-actin monoclonal antibody (diluted 1:1000; sc-130301,
Snata cruz, USA) was used.
Cell proliferation, apoptosis and migration assays
Cell proliferation was evaluated by measuring cell viabil-
ity with Cell Counting Kit-8 (CCK-8) assay (Beyotime
Inst Biotech, China) according to the manufacturer’s
instructions. Cells (2 × 103 cells per well) were plated in
96-well plates in triplicate. CCK-8 was added to each
well at a final concentration of 10 % at different time
points (24, 48, 72 and 96 h) and incubation continued at
37 °C for 50 min. Subsequently, the absorbance of the
samples was measured at 450 nm using a Multiskan
MK3 microplate reader (Thermo Labsystems, USA) to
calculate the numbers of viable cells in each well.
Apoptosis was detected by flow cytometry using the
Annexin V-APC/7-AAD Apoptosis Detection Kit (Key-
GEN, China). Briefly, cells were harvested, washed,
resuspended in the staining buffer, and doubly stained
with annexin-V and 7-amino-actinomycin D (7-AAD).
For each experiment, 5 × 104 cells were analyzed using
FACSCalibur and CellQuest software (BD Biosciences,
USA). The Annexin V-positive cells were regarded as
apoptotic cells.
Ability of cell migration was evaluated by Transwell
assay (Corning Inc, USA) according to the manufacturer’s
instructions. Cells (1.5 × 105 cells per well) in 300 μl
serum-free medium were placed in the upper chamber of
the transwell, whereas the lower chamber was loaded with
500 μl medium containing 20 % fetal bovine serum. After
16 h of incubation, cells that migrated to the lower cham-
ber were fixed and stained with crystal violet. The number
of cells was counted in five random microscopic fields
(magnification 400 ×).
Genome-wide expression microarray and pathway
analysis
Total RNA was isolated for microarray analysis from three
biological replicates of cells transfected with AGO2
shRNAs or control shRNA using TRIzol reagent (Invitro-
gen, USA) according to the manufacturer’s instructions.
All samples with an RNA integrity number (RIN) ≥ 8.0
and A260/A280 ratio 1.8-2.1 were considered suitable for
microarray analysis. The Affymetrix GeneChip® Human
Gene U133 Plus 2.0 Arrays were used for genome-
wide expression profiling assay, which was performed
by CapitalBio Corporation (Beijing, China) according
to the manufacturer’s instructions (Affymetrix, USA).
Raw feature data from microarrays were subsequently
corrected for background and normalized, and the log2 in-
tensity expression summary values for each probe set were
calculated using Robust Multiplechip Average (RMA).
Significantly altered genes following AGO2 knockdown
were analyzed by significance analysis of microarray (SAM,
version 3.01), and the P values of the t test were calculated
for each gene. Multiple hypothesis testing was per-
formed to calculate the false discovery rates (FDRs)
through the Bioconductor package Qvalue (http://www.
bioconductor.org). Significantly altered genes following
AGO2 knockdown were investigated for biological pro-
cesses and signaling pathways using the cytoscape plug-in
of Reactome FI [23].
Statistical analysis
Genotype and allele frequencies of AGO2 polymorphisms
were determined by direct counting, and departures from
Hardy-Weinberg equilibrium (HWE) were tested using
the random-permutation procedure implemented in the
Arlequin package (http://cmpg.unibe.ch/software/arle-
quin3/). Multivariate logistic regression analysis was
done to evaluate whether there were genetic associations
between the AGO2 polymorphisms and risk and severity
of NPC. The P values, odds ratios (ORs), and 95 % confi-
dence intervals (CIs) were calculated and adjusted for sex,
age, status of smoking and drinking, smoking level, family
history and nationality where it was appropriate. To assess
the probability of a spurious association due to multiple
comparisons, the online software SNPSpD (http://gump.-
qimr.edu.au/general/daleN/SNPSpD) was used to calcu-
late the correction factor for multiple testing in gene unit
[24]. A P value of 0.0036 (0.05/14.01; correction factor =
14.01) was used as the criterion of statistical significance in
Guangxi population. Association analysis was performed by
SNPStats (http://bioinfo.iconcologia.net/snpstats/start.htm).
The power for our genetic association study was calculated
using the Power for Genetic Association Analyses (PGA)
[25]. Differences of the protein expression levels detected
by IHC between the NPC tissues and non-cancerous
nasopharyngeal tissues, and between the rs3928672 GG
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genotype and A allele (GA +AA genotype) carriers were
assessed by a Wilcoxon signed-ranks test and logistic re-
gression analysis, respectively. Unpaired t test was used to
analyze the results of cell proliferation, apoptosis and mi-
gration assays. A P value of 0.05 was used as the criterion
of statistical significance, and all statistical tests were two
sided. These analyses were performed using SPSS software
(Version 17.0; SPSS Inc., USA).
Results
Characteristics of the study population
For the Guangxi population, the selected demographic
and clinical characteristics were described in detail previ-
ously (Additional file 1: Table S1) [20]. In the Guangdong
population, there was no significant difference between
the patients and control subjects in terms of mean age,
sex, status of smoking and drinking; while more heavier
smokers (≥ 24 pack-years) were present in the cases com-
pared with controls (χ2 = 13.42, P = 2.48 × 10−4). Accord-
ing to the TNM systems, 3.6 %, 14.9 %, 50.5 % and 25.4 %
of patients had stage I, II, III, and IV disease, respectively
(Additional file 1: Table S1).
Genetic association between SNPs of the AGO2 gene and
NPC
The 25 SNPs were initially genotyped in the Guangxi
population. We succeeded in genotyping 24 (with the
exception of rs2977481) out of 25 SNPs using the
SNPstream assay. Of these 24 SNPs, 2 (rs883596 and
rs2977490) were not in HWE (both P < 0.05). We there-
fore selected the remaining 22 SNPs for the subsequent
analyses.
The genotyping results for the 22 SNPs are shown in
Additional file 1: Table S4. On the basis of logistic re-
gression analysis with adjustment for sex, age, status of
smoking and drinking, smoking level, family history and
nationality, only one SNP, i.e. rs12542354, was signifi-
cantly associated with the susceptibility to NPC in the
Guangxi population after correction for multiple com-
parisons (OR = 1.32, 95 % CI = 1.13-1.54, P = 0.00040;
Additional file 1: Table S4). Then, the rs12542354 was
further genotyped in the Guangdong population. How-
ever, the initial association between the rs12542354 and
risk of NPC in the Guangxi population was not validated
in the Guangdong population (Additional file 1: Table S4).
Then, we assessed the effects of the AGO2 polymor-
phisms on the severity of NPC (as measured by TNM
staging system) in the Guangxi population. After adjust-
ment for sex, age, status of smoking and drinking, smok-
ing level, family history and nationality, logistic regression
analysis revealed that significant association with the
advanced local tumor invasion of NPC was observed
with the rs2271735 (Additional file 1: Table S5). In the
meantime, the rs2977469 and rs3928672 were significantly
associated with the advanced lymph node involvement of
NPC (Additional file 1: Table S6). The associations
remained significant even after correction for multiple
comparisons. To confirm the initial associations of these
three SNPs (rs2271735, rs2779249 and rs3928672) with
the NPC severity, the Guangdong population, com-
posed of 997 patients with NPC, were also genotyped
(Additional file 1: Table S5 and Additional file 1: Table
S6). Only rs3928672 was validated in the Guangdong
population. In the Guangxi population, the patients bear-
ing rs3928672 A allele (GA +AA genotype) had a signifi-
cantly increased frequent of involvement of lymph node
compared with ones bearing GG genotype (N3 vs. N0 +
N1 +N2; OR = 2.47, 95 % CI = 1.47-4.13, P = 0.00030;
Table 2). Consistently, patients with the rs3928672 A allele
(GA +AA genotype) had an advanced lymph node metas-
tasis (N3 vs. N0 +N1 +N2; OR = 1.75, 95 % CI = 1.03-
2.98, P = 0.034; Table 2) compared to ones with the GG
genotype in the Guangdong population. The distribution
of rs3928672 genotype frequencies is not different be-
tween the four N classification sub-populations. There-
fore, we pooled the two case-control studies from the
Guangxi and Guangdong populations, and found that
the association of rs3928672 with the susceptibility to
advanced lymph node metastasis was stronger (N3 vs.
N0 + N1 + N2; OR = 2.08, 95 % CI = 1.44-3.01, P =
8.60 × 10−5; Table 2). A meta-analysis also confirmed
the strong evidence of association of rs3928672 with the
advanced lymph node metastasis (N3 vs. N0 +N1 +N2;
OR = 2.09, 95 % CI = 1.44-3.03, P = 9.64 × 10−5; Table 2).
There was little evidence of heterogeneity among sample
sets (Pheterogeneity = 0.36).
The association between the rs3928672 A allele (GA +
AA genotype) and advanced lymph node metastasis of
NPC were further examined with stratification by age,
sex, status of smoking and drinking, smoking level, fam-
ily history and nationality (Additional file 1: Table S7). A
significantly increased risk of lymph node metastasis of
NPC was found in the heavier smokers (≥ 24 pack-years)
compared with the lighter smokers (P = 0.022, test for
homogeneity). However, the smoking level had no modi-
fication effect on the severity of NPC related to the
rs3928672 in the Guangdong population.
The power for this association study was calculated using
the PGA program [25], based on our sample sizes in the
Guangxi population (78 patients with N3 stage vs. 763
patients with N0 +N1 +N2 stage), the minor A allele fre-
quency of 31.3 %, and an OR of 2.47. By this calculation,
the power of our initial association study in the Guangxi
population to detect rs3928672 was estimated to be 44.0 %.
Effect of the rs3928672 on AGO2 protein expression
We further investigated the protein expression level of
AGO2 in NPC tissues and non-cancerous nasopharyngeal
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tissues by IHC assay. Consistent with a previous report
[12], the AGO2 protein was mainly accumulated in the
cytoplasm of malignant cells. We detected high expression
of AGO2 in the 32 of 37 NPC tissues (86.5 %), but in the
10 of 18 non-cancerous nasopharyngeal tissues (55.5 %)
(χ2 = 6.42, P = 0.011; Fig. 1 and Additional file 1: Table S8).
Furthermore, there was significant association between
the rs3928672 genotypes and expression level of AGO2
protein in the NPC tissues, with the A allele (GA +AA
genotype) carriers having higher AGO2 expression than
the GG genotype carriers (P = 0.041; Additional file 1:
Table S8).
Effect of AGO2 knockdown on cell proliferation, apoptosis
and migration in vitro
Given that the genetic variant of AGO2 is associated
with NPC progression, we speculated that AGO2, which
was over-expressed in NPC tissues, might influences the
tumorigenic properties of NPC cells. We used three
AGO2 specific shRNAs to knock down AGO2 in a
human nasopharyngeal carcinoma cell line CNE2Z, and
western blots assay confirmed that the protein expres-
sion level of AGO2 was remarkably decreased in CNE2Z
cells after AGO2 knockdown (Fig. 2a). The CCK-8 assay
was carried out to examine whether AGO2 knockdown
affected NPC cell proliferation. As shown in Fig. 2b,
CNE2Z cells transfected with AGO2 shRNAs had a
significant viability reduction over time compared with
controls (P < 0.0001), suggesting that AGO2 knockdown
significantly inhibited proliferation of NPC cells. More-
over, the percentages of apoptotic cells in CNE2Z cells
transfected with AGO2 shRNAs was increased 14.4 %
compared with controls (P < 0.0001; Fig. 2c), indicating
AGO2 knockdown induced apoptosis of NPC cells.
Furthermore, migratory cells in CNE2Z cells transfected
with AGO2 shRNAs was 36 ± 3, approximately 7.8-fold
Table 2 Genetic associations of rs3928672 with the lymph node metastasis of NPC
Populations Genotypes N classification, n (%) OR (95 % CI)a P valuea
N0 N1 N2 N3
Guangxi (n = 177) (n = 406) (n = 180) (n = 78)
GG 91 (51.4) 187 (46.1) 95 (52.8) 22 (28.2) 1.00 (reference)
GA 72 (40.7) 177 (43.6) 69 (38.3) 47 (60.3) 2.50 (1.47-4.25) 0.0010
AA 14 (7.9) 42 (10.3) 16 (8.9) 9 (11.5) 2.31 (1.01-5.27) 0.046
GA + AA 86 (48.6) 219 (53.9) 85 (47.2) 56 (71.8) 2.47 (1.47-4.13) 0.00030
Guangdong (n = 226) (n = 372) (n = 260) (n = 65)
GG 123 (54.4) 184 (49.5) 134 (51.5) 25 (38.5) 1.00 (reference)
GA 87 (38.5) 152 (40.8) 105 (40.4) 37 (56.9) 1.95 (1.14-3.34) 0.015
AA 16 (7.1) 36 (9.7) 21 (8.1) 3 (4.6) 0.79 (0.23-2.72) 0.71
GA + AA 103 (45.6) 188 (50.5) 126 (48.5) 40 (61.5) 1.75 (1.03-2.98) 0.034
Pooled (n = 403) (n = 778) (n = 440) (n = 143)
GG 214 (53.1) 371 (47.7) 229 (52.0) 47 (32.9) 1.00 (reference)
GA 159 (39.5) 329 (42.3) 174 (39.5) 84 (58.7) 2.22 (1.51-3.20) 4.07 × 10−5
AA 30 (7.4) 78 (10.0) 37 (8.5) 12 (8.4) 1.54 (0.79-2.99) 0.21
GA + AA 189 (46.9) 407 (52.3) 211 (48.0) 96 (67.1) 2.08 (1.44-3.01) 8.60 × 10−5
Overallb (n = 403) (n = 778) (n = 440) (n = 143)
GG 214 (53.1) 371 (47.7) 229 (52.0) 47 (32.9) 1.00 (reference)
GA 159 (39.5) 329 (42.3) 174 (39.5) 84 (58.7) 2.21 (1.52-3.23) 3.82 × 10−5
AA 30 (7.4) 78 (10.0) 37 (8.5) 12 (8.4) 1.66 (0.83-3.29) 0.15
GA + AA 189 (46.9) 407 (52.3) 211 (48.0) 96 (67.1) 2.09 (1.44-3.03) 9.64 × 10−5
Note: Guangxi and Guangdong populations consist of 855 and 962 patients with known lymph node involvement (N classification) stage, respectively. Due to
DNA quality and/or quantity, the actual sample sizes were 841 and 923 patients in the Guangxi and Guangdong population, respectively
Abbreviations: N lymph node involvement, OR odds ratio, CI confidence interval
aIn the Guangxi population, the ORs, 95 % CIs and P values were calculated for N3 vs. N0 + N1 + N2 and adjusted for sex, age, status of smoking and drinking,
smoking level, family history and nationality. In the Guangdong population, the ORs, 95 % CIs and P values were calculated for N3 vs. N0 + N1 + N2 and adjusted
for sex, age, status of smoking and drinking, and smoking level. In the pooled population, the ORs, 95 % CIs and P values were calculated for N3 vs. N0 + N1 + N2
and adjusted for sex, age, status of smoking and drinking, and smoking level. Another confounding factor, native place, was also adjusted in the pooled
population
bA meta-analysis combining two independent case–control studies. The P values for heterogeneity among sample sets are 0.52 for GA vs. GG group, 0.18 for AA
vs. GG and 0.36 for GA + AA vs. GG group, respectively
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lower (P < 0.0001) than those in CNE2Z cells transfected
with control shRNA (282 ± 34), suggesting AGO2 knock-
down reduced migration ability of NPC cells (Fig. 2d).
Altered gene expression in response to AGO2 knockdown
To elucidate the comprehensive regulation in transcrip-
tional profile induced by AGO2, whole-genome expression
microarray analysis was conducted between the CNE2Z
cells transfected with AGO2 shRNAs and control shRNA.
A total of 1160 genes were altered significantly, including
767 genes were down-regulated and 393 genes were up-
regulated, in CNE2Z cells after AGO2 knockdown com-
pared with controls (P < 0.05; Additional file 2: Table S9).
To determine whether specific biological processes
or signaling pathways were involved in the AGO2
knockdown-induced anticancer effects, we conducted
biological network analysis of these 1160 deferentially
expressed genes using the cytoscape plug-in of Reactome
FI [23]. Figure 3 shows some of the most significant
biological processes or signaling pathways (full list in
Additional file 3: Table S10). Remarkably, the majority of
the enriched biological processes were related to the cell
cycle, apoptosis and cell adhesion, which were hallmarks
during the development of cancers. Furthermore, signal-
ing pathways related to the tumor metastasis, namely
“Signaling by Rho GTPases” [26], “Notch signaling path-
way” [27] and “Wnt signaling pathway” [28] were also
significantly enriched. All together, these observations
indicate that AGO2 is associated with the development of
NPC by regulating expression of numerous cancer related
genes.
Discussion
In the present study, we systematically evaluated the
effect of SNPs in the AGO2 gene on the risk of occur-
rence or progression of NPC in two case–control popu-
lations of Chinese ancestry. We found that the AGO2
rs3928672 was significantly associated with the advanced
lymph node metastasis of NPC. The functional experi-
ments demonstrated that the genotype of rs3928672 was
significantly associated with the expression of AGO2 in
NPC tissues, and AGO2 can play an oncogenic role in
the development of NPC by regulating genes related to
the tumorigenesis and metastasis. To the best of our
knowledge, this is the first report that the genetic poly-
morphisms of AGO2 may be risk factor for the progres-
sion of NPC, and AGO2 acts as an oncogene in NPC.
The polymorphisms in the AGO2 gene have been used
to search for susceptibility alleles of a wide spectrum of
cancers (Additional file 1: Table S11). For instance, three
SNPs, i.e. rs3864659, rs2292779 and rs11786030, in the
AGO2 gene were shown to be associated with breast
cancer in Korea population [17, 18]. Unfortunately, on
the basis of analysis of 855 NPC cases and 1036 controls
in the Guangxi population, we did not find a statistically
significant association between these SNPs and the sus-
ceptibility to NPC. The inconsistent results may be attrib-
uted to different molecular mechanisms of carcinogenesis
Fig. 1 Protein expression level of AGO2 by immunohistochemical staining in representative NPC tissues and non-cancerous nasopharyngeal
tissues. Panels a and b NPC tissues; Panels c and d non-cancerous nasopharyngeal tissues. Images in the box (left, magnification 200 ×) were
enlarged and shown in the right (magnification 400 ×). The AGO2 protein was found to locate in the cytoplasm of malignant cells
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among cancers, small sample size, marginal statistical
significance and different ethnicities of study populations.
However, by using the tag SNP approach, we identified a
novel tag SNP (i.e. rs3928672) that was associated with
the risk of lymph node metastasis of NPC in two Chinese
subpopulations. Together, our results support the AGO2
gene as a susceptibility gene for cancers.
In both study populations, the subjects bearing the
rs3928672 A allele (GA +AA genotype) had a significantly
increased frequency of involvement of lymph node metas-
tasis of NPC compared with ones bearing GG genotype.
Moreover, the rs3928672 A allele carriers having higher
AGO2 protein expression than the GG genotype carriers
in NPC tissues. Given the role of AGO2 in the develop-
ment of NPC, one might expect individuals who carry the
rs3928672 A allele, and thus have increased expression of
AGO2 over a lifetime, may have a higher risk of develop-
ing lymph node metastasis of NPC after establishment of
this malignancy. However, the rs3928672, which is a poly-
morphism in intron 4 of AGO2, may not have a functional
consequence. It is plausible that some other functional
polymorphisms in linkage disequilibrium (LD) with the
Fig. 2 The effect of AGO2 knockdown on proliferation, apoptosis and migration of NPC cells. a Confirmation of AGO2 knockdown in CNE2Z cells
transfected with AGO2 shRNAs or control shRNA by western blot assay. b Cell proliferation was evaluated by CCK-8 assay in CNE2Z cells transfected
with AGO2 shRNAs or control shRNA at different time points (24, 48, 72 and 96 h). The experiments were repeated at least three times, and the points
represent the mean values of triplicate tests (mean ± SD). ***P < 0.0001, compared with the controls (ANOVA test). c Apoptosis was assessed by flow
cytometric analysis of annexin V-APC/7-AAD staining in CNE2Z cells transfected with AGO2 shRNAs or control shRNA. Representative flow cytometric
analysis are shown (left panel). The Annexin V-positive cells were regarded as apoptotic cells. The experiments were repeated at least three times, and
the histogram (right panel) represents the mean values of apoptotic cells from triplicate tests (mean ± SD). ***P < 0.0001, compared with the controls
(Unpaired t test). d Cell migration was evaluated by transwell assay in CNE2Z cells transfected with AGO2 shRNAs or control shRNA. Representative
results are shown (left panel). Magnification: 400 ×. The experiments were repeated at least three times, and the histogram (right panel) represents the
mean numbers of transferred cells from triplicate tests (mean ± SD). ***P < 0.0001, compared with the controls (Unpaired t test). CCK-8, Cell Counting
Kit-8; SD, standard deviation
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rs3928672 should be responsible for the allele-specific
expression. However, the rs3928672 is in low linkage
disequilibrium with other SNPs in both the patients and
comparison subjects in the Guangxi population as well as
in the HapMap CHB (r2 < 0.80), indicating that the associ-
ation of rs3928672 with NPC severity is likely independ-
ent. Alternatively, we cannot exclude the possibility that
the rs3928672 itself is a functional variant directly affect-
ing the AGO2 production. Introns in eukaryotes fulfill a
broad spectrum of functions, such as acting as transpos-
able elements, and are involved in virtually every step of
mRNA processing [29]. Indeed, by computer analysis
(F-SNP database, http://compbio.cs.queensu.ca/F-SNP)
we found that the polymorphism rs3928672 maybe influ-
ence binding of transcription factor RUNX1 (runt-related
transcription factor 1, also called AML-1) and CAP1
[CAP, adenylate cyclase-associated protein 1 (yeast)], since
the sequences flanking rs3928672 A allele (5’-AGTGGT-
3’) as a potential binding site for the RUNX1, and the
sequences flanking G allele (5’-TCACCGCT-3’) as a
potential binding site for the CAP1, respectively. There-
fore, one mechanism by which this could occur is if the
Fig. 3 The most enriched biological processes and signaling pathways of the 1160 genes with significantly altered expression following AGO2
knockdown in CNE2Z cells by cytoscape plug-in of Reactome FI analysis. “G” represents “GO biological process”, “K” represents “KEGG pathway”,
“N” represents “NCI PID”, “R” represents “Reactome”, “P” represents “Reactome Pathway” and “B” represents “BioCarta”. The detailed results were
shown in Additional file 3: Table S10
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risky rs3928672 A allele can influence binding of tran-
scription factor in the intron 4 of AGO2. Further studies
are needed to clarify which polymorphism(s) may possess
functional consequence(s) for AGO2, and in turn to pro-
vide mechanistic plausibility for the observed association
between rs3928672 and involvement of lymph node
metastasis of NPC.
The mechanism of how AGO2 SNPs regulates human
susceptibility to cancer is unknown. However, AGO2 has
significant roles controlling the tumorigenesis and pro-
gression of several cancers, including tumor invasion and
metastasis [8–10, 14, 15]. This processes appears to be
through two different molecular mechanisms, RNAi-
dependent gene silencing [8, 30] and RNAi-independent
ways such as stabilizing insulator-independent looping
[31], facilitating DNA double-strand break repair [32], tar-
geting the intragenic long interspersed nuclear element-1
(LINE-1) transcription complexes [33], and directly regu-
lating downstream gene expression [9]. Consistent with
the previous study, we showed that the AGO2 protein was
significantly over-expressed in NPC tissues compared with
non-cancerous nasopharyngeal epithelium tissues in the
present study. Moreover, functional experiments illustrate
that AGO2 knockdown reduced cell proliferation, induced
apoptosis, and inhibited migration of NPC cells. These
effects of AGO2 knockdown were further corroborated by
genes with altered expression following AGO2 knock-
down, which were functionally clustered in biological
processes related with cell cycle, apoptosis and cell migra-
tion. Furthermore, several tumorigenesis and metastasis
associated genes with altered expression following AGO2
knockdown were targets of miRNAs (e.g., TPBG [34], JUP
[35], CDKN1A [36] and S100A11 [37] were experimentally
validated targets of miR-155 [38, 39]). Therefore, AGO2
may promote tumorigenesis and metastasis by regulating
miRNAs and their targets in NPC. Taken together, our
findings indicated that AGO2 over-expression can con-
tribute to NPC malignant behaviors.
In reviewing the results of this study, one must also
keep several potential limits in mind. First, as a hospital-
based study, our NPC cases were recruited from the
hospital, while the controls were selected from the
community population; inherent selection bias cannot
be completely excluded. However, by further adjustment
and stratification in data analyses, the potential con-
founding effects might have been minimized. Second, a
number of association studies have addressed identifying
the genes that may relate to the susceptibility to NPC
[40–42]. Most of the results, however, could not be
replicated in subsequent studies in other populations.
Although the highly significant association between the
AGO2 and lymph node metastasis of NPC was strength-
ened by our two independent case–control studies, our
initial findings should be independently verified in other
populations with high incidence rate of NPC, such as
other Southern Chinese, Singaporeans, and Taiwanese.
Conclusions
In conclusion, we have shown that the AGO2 polymorph-
ism may be a genetic risk factor for NPC in Chinese
population. If confirmed by other studies, knowledge of
genetic factors contributing to the pathogenesis of the
NPC as presented here may have implications for the
cancer screening and treatment of this disorder.
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